J&J looks to sell feminine products unit; Pfizer nabs broader use for Prevnar 13;

@FiercePharma: Another Bayer drug gets the eye from French regulators: Acne drug/BCP Diane-35 linked to 4 deaths, ANSM says. More | Follow @FiercePharma

 @AlisonBFierce: GSK formed a joint venture in India to produce a 6-in-1 vaccine that will immunize children in developing countries. News | Follow @AlisonBFierce

> Johnson & Johnson ($JNJ) is shopping its feminine products business, The Wall Street Journal reports, as part of an effort to shed bits of the company that don't fit its growth strategies. Report

> Pfizer ($PFE) won another new use for its Prevnar 13 vaccine, broadening its market to children 6 years to 17 years old; the pneumococcal shot is now Pfizer's leading product. Report

> Merck ($MRK) won approval to market its overactive bladder patch Oxytrol over the counter. Report

> The new Actavis, created with Watson Pharmaceuticals' ($WPI) buyout of the Swiss generics maker Actavis, terminated an insulin marketing deal with biosimilars maker Bioton. Report

> The U.S. has asked for an exemption from new European rules for active pharmaceutical ingredients. Report

> Mexico's Genomma bought the Argentine painkiller brand Tafiral for $26.94 million. Report

Medical Device News

 @FierceMedDev: UNC team identifies Dx to spot worsening macular degeneration. News | Follow @FierceMedDev

 @MarkHFierce: The Netherlands' Medisse nailed down a $3.5M US Series B to fund development of a bioresorbable material for implants. Release | Follow @MarkHFierce

 @DamianFierce: That rumored Quintiles IPO may finally be around the corner, anon. sources tell Reuters, Bloomberg. News | Follow @DamianFierce

> Medisse raises $3.5M for new med device biomaterial. Article

> Given Imaging is no longer selling itself, but an EU investor wants a piece. More

Biotech News

 @FierceBiotech: Keryx shares soar on upbeat PhIII results for CKD drug Zerenex. Article | Follow @FierceBiotech

@JohnCFierce: New bidness model: VCs launch another biotech with late-stage R&D model for Big Pharma--(think SFJ). More | Follow @JohnCFierce

@RyanMFierce: FDA called out in study of smartphone apps for melanoma. Report | Follow @RyanMFierce

> Idenix moves out of FDA limbo with J&J hep C combo pact. Story

> Takeda grabs long-awaited U.S. approval for diabetes drug Nesina. News

Biotech IT News

> FDA called out in study of smartphone apps for melanoma. Article

> Big Data analysis takes on childhood brain cancer. Story

> Hopkins mines Twitter for real flu cases in real time. More

> NIH supports Parkinson's research with online collaboration. Item

CRO News

> Is Quintiles finally going public? Article

> Covance soars on 60% income growth in Q4. Report

> GVK teams up with Endo on early-stage pain drug. Story

> Indian Supreme Court wants answers on clinical trials. More

And Finally... A flood of lawsuits challenges new U.S. rules requiring employer-provided health plans to provide contraceptives at no cost to their members. Report (sub. req.)

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.